Siemens Healthineers has inaugurated a €10 million Centre of Excellence for Immunoassay Instrument R&D in Swords, Dublin, enhancing Ireland’s medtech and life sciences manufacturing capabilities. 

The facility, adjacent to existing production operations, is part of a multi-year investment plan begun in 2023 according to a Mass Device report.

The centre focuses on instruments for detecting infectious diseases, cancer, and blood disorders. It employs over 65 specialists in software engineering, hardware design, bioscience, data science, systems engineering, and AI. Siemens Healthineers notes the team “work globally with R&D colleagues on next-generation instrument design” and use advanced digital manufacturing tools and automation to meet demand for high-precision diagnostic testing.

The site continues developing the Atellica family of analysers, designed to deliver “greater flexibility and efficiency in clinical laboratories worldwide,” enabling faster turnaround times, higher throughput, and improved precision.

The company received a multi-million euro training grant from IDA Ireland to fund a 3–5-year upskilling programme across engineering, operations, and leadership.

Patrick Grimes, global head of hardware engineering R&D, said, “For nearly 60 years, this site has delivered world-class diagnostic instruments to hospitals and laboratories globally. Now, by aligning research and development with production under one roof, we are accelerating the pace of discovery and delivery.”

Darragh O’Brien added, “The innovations and products developed here in Ireland will have a truly global reach, reflecting the strong culture of collaboration between industry, research and talent that we are proud to support.”

Read the full report on Siemens Healthineers’ Swords R&D expansion and its impact on advanced manufacturing.